Kura Oncology (KURA) Debt to Equity (2023 - 2025)
Kura Oncology (KURA) has disclosed Debt to Equity for 3 consecutive years, with $0.06 as the latest value for Q4 2025.
- On a quarterly basis, Debt to Equity rose 142.23% to $0.06 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.06, a 142.23% increase, with the full-year FY2025 number at $0.06, up 142.23% from a year prior.
- Debt to Equity was $0.06 for Q4 2025 at Kura Oncology, up from $0.04 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.06 in Q4 2025 to a low of $0.02 in Q1 2024.
- A 3-year average of $0.03 and a median of $0.02 in 2023 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: decreased 20.26% in 2024, then soared 142.23% in 2025.
- Kura Oncology's Debt to Equity stood at $0.02 in 2023, then decreased by 1.99% to $0.02 in 2024, then skyrocketed by 142.23% to $0.06 in 2025.
- Per Business Quant, the three most recent readings for KURA's Debt to Equity are $0.06 (Q4 2025), $0.04 (Q3 2025), and $0.03 (Q2 2025).